Osawa Gakuji, Yoshimatsu Kazuhiko, Yokomizo Hajime, Matsumoto Atsuo, Yano Yuki, Itagaki Hiroko, Otani Taisuke, Fujimoto Takashi, Umehara Arihiro, Ogawa Kenji
Dept. of Surgery, Tokyo Women's Medical University Medical Center East.
Gan To Kagaku Ryoho. 2010 Nov;37(11):2189-91.
We reported two cases of colorectal cancer patients with EGFR-positive unresectable synchronous liver metastasis effectively treated by cetuximab after the progression of the prior chemotherapy. Case 1: A 49-year-old female with unresectable synchronous liver metastasis from colon cancer received cetuximab monotherapy as fifth-line therapy. Then, abdominal CT showed shrinkage of the liver metastasis (PR) and the performance status was improved from 3 to 0 as upper abdominal pain reduced. Case 2: A 67-year-old female with unresectable liver metastasis from colon cancer received cetuximab with CPT-11 combined therapy as fourth-line therapy. After that, liver metastasis also decreased (PR), and upper abdominal pain and PS were improved from 2 to 0. These two cases of KRAS status on cancer tissue also showed wild-type, and in these cases cetuximab proved effective.
我们报告了两例患有表皮生长因子受体（EGFR）阳性且不可切除的同步性肝转移的结直肠癌患者，在先前化疗进展后接受西妥昔单抗治疗取得了有效疗效。病例1：一名49岁女性，患有来自结肠癌的不可切除同步性肝转移，接受西妥昔单抗单药治疗作为五线治疗。之后，腹部CT显示肝转移灶缩小（部分缓解），且随着上腹部疼痛减轻，其体能状态从3改善至0。病例2：一名67岁女性，患有来自结肠癌的不可切除肝转移，接受西妥昔单抗与伊立替康联合治疗作为四线治疗。此后，肝转移灶也缩小（部分缓解），上腹部疼痛和体能状态从2改善至0。这两例患者癌组织的KRAS状态也显示为野生型，在这些病例中西妥昔单抗被证明有效。
